Combined neutral endopeptidase inhibitors

Bibliography

• Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371(9623):1513-18
   PubMed Web of Science ®Google Scholar
• Meyer K, Simmet A, Arnold M, Stroke events, and case fatalities in Switzerland based on hospital statistics and cause of death statistics. Swiss Med Wkly 2009;139(5-6):65-9
   PubMed Web of Science ®Google Scholar
• Conen D, Chae CU, Guralnik JM, Glynn RJ. Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly. Swiss Med Wkly 2010;140(13-14):202-8
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536
   PubMed Web of Science ®Google Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley H, Mayosi BM, Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;(1):CD002003
   Google Scholar
• Saini-Chohan HK, Hatch GM. Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure. Curr Drug Metab 2009;10(3):206-19
   PubMed Web of Science ®Google Scholar
• Werner C, Poss J, Bohm M. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy? Drugs 2010;70(10):1215-30
   PubMed Web of Science ®Google Scholar
• Krum H, Maggioni A. Renin inhibitors in chronic heart failure: the Aliskiren observation of heart failure treatment study in context. Clin Cardiol 2010;33(9):536-41
   PubMed Web of Science ®Google Scholar
• Corti R, Burnett JC Jr, Rouleau JL, Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104(15):1856-62
   PubMed Web of Science ®Google Scholar
• Margulies KB, Barclay PL, Burnett JC Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995;91(7):2036-42
   PubMed Web of Science ®Google Scholar
• Graf K, Koehne P, Grafe M, Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995;26(2):230-5
   PubMed Web of Science ®Google Scholar
• Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3(2):145-51
   PubMed Web of Science ®Google Scholar
• Dussaule JC, Stefanski A, Bea ML, Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1993;264(1 Pt 2):F45-52
   PubMed Web of Science ®Google Scholar
• Stephenson SL, Kenny AJ. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987;243(1):183-7
   PubMed Web of Science ®Google Scholar
• Lang CC, Motwani JG, Coutie WJ, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci (Lond) 1992;82(6):619-23
   PubMed Web of Science ®Google Scholar
• Murphy LJ, Corder R, Mallet AI, Turner AJ. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol 1994;113(1):137-42
   PubMed Web of Science ®Google Scholar
• Ando S, Rahman MA, Butler GC, Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26(6 Pt 2):1160-6
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Pfeffer MA, Stewart DJ, Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356(9230):615-20
   PubMed Web of Science ®Google Scholar
• Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 1998;64(4):439-49
   PubMed Web of Science ®Google Scholar
• Norton GR, Woodiwiss AJ, Hartford C, Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999;12(6):563-71
   PubMed Web of Science ®Google Scholar
• Allikmets K. Sampatrilat shire. Curr Opin Investig Drugs 2002;3(4):578-81
   PubMedGoogle Scholar
• Dussaule JC, Grange JD, Wolf JP, Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab 1991;72(3):653-9
   PubMed Web of Science ®Google Scholar
• Varin J, Duboc D, Weber S, Effect of sinorphan, an endopeptidase inhibitor on severe congestive cardiac insufficiency. Arch Mal Coeur Vaiss 1991;84(10):1465-71
   PubMedGoogle Scholar
• Kahn JC, Patey M, Dubois-Rande JL, Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990;335(8681):118-19
   PubMed Web of Science ®Google Scholar
• Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 1998;351(9116):1657-8
   PubMed Web of Science ®Google Scholar
• Maertins T, von Keutz E, Goetze L. Acute, subchronic, and chronic toxicity of ecadotril in dogs. Am J Vet Res 2000;61(4):425-9
   PubMed Web of Science ®Google Scholar
• O'Connor CM, Gattis WA, Gheorghiade M, A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J 1999;138(6 Pt 1):1140-8
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Ohkubo T, Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. J Renin Angiotensin Aldosterone Syst 2002;3(4):270-6
   PubMed Web of Science ®Google Scholar
• Regamey F, Maillard M, Nussberger J, Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 2002;40(3):266-72
   PubMed Web of Science ®Google Scholar
• Mitchell GF, Izzo JL Jr, Lacourciere Y, Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002;105(25):2955-61
   PubMed Web of Science ®Google Scholar
• Palmieri V, Devereux RB, Hollywood J, Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: the Strong Heart Study. Am J Hypertens 2006;19(6):601-7
   PubMed Web of Science ®Google Scholar
• Raitakari OT, Juonala M, Taittonen L, Pulse pressure in youth and carotid intima-media thickness in adulthood: the cardiovascular risk in young Finns study. Stroke 2009;40(4):1519-21
   PubMed Web of Science ®Google Scholar
• Bangalore S, Messerli FH, Franklin SS, Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. Eur Heart J 2009;30(11):1395-401
   PubMed Web of Science ®Google Scholar
• Kostis JB, Packer M, Black HR, Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17(2):103-11
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106(8):920-6
   PubMed Web of Science ®Google Scholar
• Piedimonte G, Nadel JA, Long CS, Hoffman JI. Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res 1994;75(4):770-9
   PubMed Web of Science ®Google Scholar
• Schriefer JA, Broudy EP, Hassen AH. Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion. J Pharmacol Exp Ther 2001;298(3):970-5
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Ivleva AY, Ujda M, Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. Am J Cardiol 2005;95(11):1283-9
   PubMed Web of Science ®Google Scholar
• Hoover T, Lippmann M, Grouzmann E, Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010;40(1):50-61
   PubMed Web of Science ®Google Scholar
• Cuculi F, Suter Y, Erne P. Angioedema of the tongue. CMAJ 2008;178(9):1136
   PubMed Web of Science ®Google Scholar
• Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002;25(2):73-6
   PubMed Web of Science ®Google Scholar
• Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006;26(4):725-37
   PubMed Web of Science ®Google Scholar
• McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332(7551):1177-81
   PubMed Web of Science ®Google Scholar
• Rubinstein I, Muns G, Zucker IH. Plasma exudation in conscious dogs with experimental heart failure. Basic Res Cardiol 1994;89(5):487-98
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Bohm M, Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375(9722):1255-66
   PubMed Web of Science ®Google Scholar
• Klapholz M, Thomas I, Eng C, Effects of omapatrilat on hemodynamics and safety in patients with heart failure. Am J Cardiol 2001;88(6):657-61
   PubMed Web of Science ®Google Scholar
• McClean DR, Ikram H, Mehta S, Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. J Am Coll Cardiol 2002;39(12):2034-41
   PubMed Web of Science ®Google Scholar